Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche and Isis Pharmaceuticals Form Alliance for Huntington's Disease

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
This alliance combines Isis' antisense expertise with Roche's scientific expertise in developing neurodegenerative therapeutics.

In addition, Isis and Roche will be collaborating to combine Isis' ASOs and Roche's proprietary "brain shuttle" program with the objective of increasing the brain penetration of ASOs with systemic administration.

Huntington's disease is an inherited genetic brain disorder that results in the progressive loss of both mental faculties and physical control. Symptoms usually appear between the ages of 30 to 50, and worsen over a 10 to 25 year period. Ultimately, the weakened individual succumbs to pneumonia, heart failure or other complications. Presently, there is no effective treatment or cure for the disease, and current treatments focus on reducing the severity of some disease symptoms.

Initially, research will focus on Isis' lead drug candidate that blocks production of all forms of the huntingtin (HTT) protein, the protein responsible for HD and thus has the potential to treat all HD patients. Isis is also conducting research into treatments that specifically block production of the disease-causing forms of the HTT protein which has the potential to treat subsets of HD patients. In parallel, Roche will combine its proprietary brain shuttle technology with Isis ASO technology that, if successful, will also allow systemic administration of antisense drugs to treat asymptomatic patients.

Under the terms of the agreement, Roche will make an upfront payment of $30 million to Isis, with total payments related to license fee and pre- and post-licensing milestone payments reaching potentially $362 million, including up to $80 million in potential commercial milestone payments. In addition, Isis will receive tiered royalties on sales of the drugs. Roche has the option to license the drugs from Isis through the completion of the first Phase 1 trial. Prior to option exercise, Isis is responsible for the discovery and development of an antisense drug targeting HTT protein. Roche and Isis will work collaboratively on the discovery of an antisense drug utilizing Roche's "brain shuttle" program. If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for all drugs arising out of the collaboration.

Commenting on the deal, Luca Santarelli, Head of Neuroscience and Small Molecules Research at Roche, said: "Huntington's is a severely debilitating neurodegenerative disease and a large unmet medical need. Patients experience gradually worsening motor function and psychological disturbances, with a significant shortening of life expectancy after the disease is diagnosed. Treatments are urgently needed, and we believe that the Isis approach in combination with Roche's brain shuttle represent one of the most advanced programs targeting the cause of HD with the aim of slowing down or halting the progression of this disease."

Shafique Virani, Global Head Neuroscience, Cardiovascular & Metabolism at Roche Partnering, added: "Central to the partnership is Roche's brain shuttle program, which we see as highly complementary to Isis' drug development work. This dual track development program ensures whichever candidate compound proves to be most promising -- Isis' lead target or Roche's brain shuttle version -- can be taken forward to pivotal clinical trials."

"We are pleased to be working with Roche, a global leader in drug development with significant experience in developing and commercializing drugs to treat neurological diseases. We believe that Roche's expertise in developing CNS drugs, along with their clinical development experience, will greatly enhance our development efforts for this program and allow us to move forward more rapidly. In addition, by utilizing Roche's brain shuttle technology with our antisense drug discovery capabilities, we have the potential to significantly improve the therapeutic potential for this program," said B. Lynne Parshall, Chief Operating Officer of Isis. "By partnering our more complex and nuanced research and development programs earlier in development, like our Huntington's disease CNS program, we add value and resources with partners that bring unique benefits."

"We are excited to be working with Roche," said Frank Bennett, Senior Vice President of Research at Isis. "We believe our mature antisense drug discovery platform is a perfect fit for Roche's neuroscience franchise, and we anticipate a fruitful collaboration to advance our pre-clinical compounds."

CHDI Foundation, a non-profit foundation exclusively dedicated to the development of therapies that slow the progression of HD, provided financial and scientific support to Isis' HD drug discovery program through a development collaboration with Isis. CHDI's support has enabled Isis to make significant progress in discovering a drug to treat HD. Together Isis and CHDI demonstrated that antisense compounds can be used to inhibit the production of HTT protein in both brain and peripheral tissues, and that the inhibition of normal HTT protein was well tolerated. Over time, CHDI will be reimbursed for its support of Isis' program out of the milestone payments received by Isis. CHDI will receive $1.5 million associated with the signing of the Roche agreement. CHDI will continue to provide advice to Isis and Roche on the development of antisense drugs to treat patients with HD.

Isis also recognizes the tremendous benefit provided to its HD program by its academic collaborators, Drs. Don Cleveland at the Ludwig Institute, University of California San Diego and David Corey at University of Texas Southwestern. These collaborators have been instrumental in Isis' early preclinical work demonstrating that antisense drugs can inhibit the HTT protein and produce activity in animal models of disease.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approves Roche’s Advanced Cervical Cancer Chemotherapy
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
Monday, August 18, 2014
Roche to Acquire Seragon Pharmaceuticals
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer.
Wednesday, July 02, 2014
Roche Recieves FDA Approval for Cervical Cancer Screening HPV Test
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older.
Friday, April 25, 2014
Roche, Oryzon Announce Epigenetics Collaboration
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions.
Monday, April 07, 2014
FDA Recommends Roche's HPV Test as Primary Screening Tool
Test will assess risk of cervical cancer of women 25 years and older.
Thursday, March 13, 2014
Roche and Molecular Partners Enter into Alliance
Partnership will combine novel biologics with Roche drug-conjugate technology to develop new cancer treatments.
Wednesday, December 04, 2013
FDA Approves New Streamlined Workflow Option for Roche's Cobas HPV Test
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow.
Friday, June 28, 2013
Roche 454 Sequencing Systems Successfully Resolve Genetic Mutations in Blood Cancer Cases
International study presented at ASH Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions.
Thursday, December 13, 2012
Is Lunar Dust Harmful to Humans?
Exposure to lunar dust during the Apollo missions resulted in reports of ocular, respiratory and dermal irritation, suggesting that lunar dust is a potential risk to human health.
Sunday, April 17, 2011
Roche’s Assay for 2009 H1N1 Influenza Virus is Regularly Updated with the Latest Virus Sequences
The assay has been developed to provide a rapid means of identification of infected patients.
Thursday, December 03, 2009
Roche’s xCELLigence System for Determination of Optimal Time Points for Gene and Protein Expression Analysis
The xCELLigence RTCA System from Roche Applied Science allows for label-free, continuous monitoring of cell phenotypic changes using electrical impedance as readout. The interaction of cells with the electronic biosensors leads to the generation of a cell-electrode impedance response which indicates the status of the cells in terms of cell number, cell viability, cell morphology and cell attachment quality. Real-time, continuous measurement ensures the documentation of cell phenotypes in the fo
Friday, August 14, 2009
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!